Check Out Our Recent Posts
Promising New Data Demonstrates Chemo-Immunotherapy Treatment Approach with ECI® Significantly Improves Outcomes in Dogs with Bone Cancer
LENEXA, Kan. – September 23, 2025 – ELIAS Animal Health, a leader in advancing novel therapies for veterinary cancer care, has published new data from [...]
ELIAS Animal Health to Present New Research at Upcoming Human and Veterinary Oncology Conferences
LENEXA, Kan., September 4, 2025 -- ELIAS Animal Health, a leader in advancing innovative therapies for veterinary oncology, today announced that it will present promising [...]
Immunotherapy Combined with a Single Dose of Chemotherapy Shows Improved Outcomes in Dogs with Bone Cancer
Recently, ELIAS Animal Health announced new data on a chemo-immunotherapy approach using the ELIAS Cancer Immunotherapy (ECI®) to treat canine osteosarcoma that demonstrated improved outcomes. [...]
More Than a Cancer Vaccine
The ELIAS Cancer Immunotherapy (ECI®) if the first and only USDA-approved product for the treatment of canine osteosarcoma. ECI® is unique because of its dual approach to treatment: it brings together the power of a personalized cancer vaccination and activated “killer” T cell therapy to trigger the patient’s own immune system to attack cancer cells. Our immunotherapy enables veterinary care providers like you to:
Extend hope for families of pets with cancer
Make a measurable difference for your patients
Help improve outcomes with minimal adverse side effects